Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 07/07/2025 pm IST			5-day change	1st Jan Change
441.20 ^DKK	-2.24%		+0.85%	-29.32%

07/07	Italy set to speed through $2.3 billion Novo Nordisk investment	RE
07/07	Italy set to speed through $2.3 billion Novo Nordisk investment	RE

Mark Cuban's Cost Plus partners with telehealth firm to offer employers obesity care drugs

Published on 17/06/2025 at 23:08, updated on 18/06/2025 at 00:18

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE
The importance of being constantly changing…	07/07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
European shares fall as banks, mining stocks losses weigh	04/07	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	04/07	FW
SAP Becomes Europe's Most Valuable Company as Nvidia Leads Globally	03/07	RE
NOVO NORDISK : UBS reiterates its Buy rating	03/07	ZD
Ascletis Pharma Begins Dosing Subjects in US Weight Management Drug Study; Shares Gain 3%	03/07	MT
How did Novo Nordisk lose the US market?	02/07
Novo Nordisk, WeightWatchers Expand Collaboration for Enhanced Access to Wegovy	02/07	MT
WW International, Inc. and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care	02/07	CI
How Novo Nordisk misread the US market for its weight loss sensation	02/07	RE
How Novo Nordisk misread the US market for its weight loss sensation	02/07	RE
Sector Update: Health Care Stocks Advance Tuesday Afternoon	01/07	MT
European Equities Close Mixed in Tuesday Trading; Euro Area Inflation Rises to 2%	01/07	MT
Top Midday Stories: Powell Blames Tariffs for Rate Pause; Tesla Shares Fall on Trump-Musk Feud	01/07	MT
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	01/07	MT
China's Innogen expects to complete weight-loss drug trials next year	01/07	RE
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	01/07	MT
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	01/07	MT
Berenberg Cuts Zealand Pharma's Price Target Amid Increased Competition	01/07	MT
NOVO NORDISK : Receives a Buy rating from UBS	01/07	ZD
Goldman Sachs Lowers Novo Nordisk Price Target to 745 Danish Kroner (from 775), Reiterates Buy - BN	01/07	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06/08 - Q2 2025 Earnings Release

More about the company